Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Milei Threatens Falkland Oil Firms With Sanctions 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Anthropic IPO Marketing Expected to Start in Mid-October 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Add as a preferred source on Google
CAMBRIDGE, Mass., Feb. 27, 2018 -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing treatments for severe neurological diseases, today announced its fourth quarter and full year 2017 financial results and corporate highlights conference call and live webcast scheduled for Wednesday, March 14, 2018 at 8:00 a.m. EDT.
The live call may be accessed by dialing (877) 851-3834 for domestic callers, or +1 (631) 291-4595 for international callers, and referencing conference ID number 3688788. A live audio webcast of the conference call will be available online from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. The webcast will be archived for 30 days.
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company’s pipeline focuses on severe neurological diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of ALS, Huntington’s disease, Friedreich’s ataxia, frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, with AbbVie, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com.
Investor Relations:
Matt Osborne
Vice President, Investor Relations & Corporate Communications
857-259-5353
[email protected]
Media:
Katie Engleman
Pure Communications, Inc.
910-509-3977
[email protected]
